CNDO 109

Drug Profile

CNDO 109

Alternative Names: Allogeneic tumour activated natural killer lymphocytes; CNDO-102; CNDO-109; CNDO-109-AANK Cells; CNDO-109-activated allogeneic NK cell therapy

Latest Information Update: 21 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University College London
  • Developer Fortress Biotech
  • Class Antineoplastics; Biological intercellular signalling peptides and proteins
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 21 Sep 2015 CNDO 109 is still in phase I/II trials for Acute myeloid leukaemia (Prevention of relapse) in the USA
  • 27 Apr 2015 Coronado Biosciences is now called Fortress Biotech
  • 28 Nov 2012 Phase-I/II clinical trials in Acute myeloid leukaemia (prevention of relapse) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top